Biomarker test is based on technology developed at WashU Medicine
FDA clears blood test to aid evaluation for Alzheimer’s disease (Links to an external site)
Category: Advancements in Alzheimers disease
Cure Alzheimer’s Fund presents the 2026 Jeffrey L. Morby Prize for Exceptional Research (Links to an external site)
Prize Recognizes Drs. Randall J. Bateman and Kanta Horie of Washington University School of Medicine in St. Louis, and Drs. Oskar Hansson and Gemma Salvadó of Lund University, Sweden
St. Louis researchers receive recognition for groundbreaking Alzheimer’s diagnostic test (Links to an external site)
Washington University professors and C2N Diagnostics co-founders Dr. Randall Bateman and Dr. David Holtzman will receive the 2026 American Innovator Award from the Bayh-Dole Coalition in Washington, D.C., on June 3.
Single Test Could Predict Alzheimer’s Symptoms Before They Even Begin (Links to an external site)
A single blood test may be able to predict when a person will develop Alzheimer’s symptoms—years before memory loss begins—according to new research from the Washington University School of Medicine in St Louis.
How Your Brain’s Nightly Cleanse Keeps It Healthy (Links to an external site)
Washing waste from the brain is an essential function of sleep—and it could help ward off dementia
Drug to slow Alzheimer’s well tolerated outside of clinical trial setting (Links to an external site)
Side effects of lecanemab are manageable, study finds
New blood test diagnoses Alzheimer’s disease and measures how far it’s progressed (Links to an external site)
The new test could also help confirm whether Alzheimer’s or another condition is causing a person’s symptoms.
Predicting cognitive decline in Alzheimer’s (Links to an external site)
New tests of blood and spinal fluid can show how far Alzheimer’s has progressed and how fast a patient’s memory will decline.
Can a Drug Prevent Alzheimer’s Disease Decades Before It Happens? (Links to an external site)
Scientists are testing an experimental anti-amyloid antibody in people expected to develop early-onset Alzheimer’s.
New drug targets for Alzheimer’s identified from cerebrospinal fluid (Links to an external site)
Study pegs certain cellular activities to driving Alzheimer’s disease. Researchers at Washington University School of Medicine in St. Louis have linked disease-related proteins and genes to identify specific cellular pathways responsible for Alzheimer’s genesis and progression.